A public risk pool in Illinois is taking on some of the biggest names in pharma and health insurance over insulin pricing.
Park District Risk Management Agency, which provides self-funded health coverage for roughly 2,765 beneficiaries across Illinois park districts, filed a suit on January 7, 2026, in federal court in New Jersey. The case lands in an existing multidistrict litigation - MDL No. 3080 - already examining how insulin gets priced and sold in the United States.
The defendants read like a who's who of the pharmaceutical and pharmacy benefit manager world. On the manufacturing side: Eli Lilly, Novo Nordisk, and Sanofi, which together accounted for 92% of global diabetes drug sales by volume in 2020. On the PBM side: CVS Caremark, Express Scripts, and OptumRx - firms that, along with their affiliated insurers Aetna, Cigna, and UnitedHealthcare, handle more than 80% of pharmacy benefit management in the country.
The agency alleges these companies ran what it calls an "Insulin Pricing Scheme." The mechanics, as described in court filings, work like this: manufacturers set artificially high list prices, then funnel a portion back to PBMs through rebates, administrative fees, and other payments. In exchange, PBMs allegedly gave those pricier insulins preferred spots on their formularies—the drug lists that determine what health plans will cover.
The numbers are striking. List prices for some insulins climbed as much as 1,000% over two decades, according to the filing, even as production costs decreased. The agency says it contracted with CVS Caremark for PBM services from 2002 through 2025 and paid prices tied to those inflated figures.
What makes this case particularly relevant for the insurance industry is its focus on rebate aggregators—entities like CVS's Zinc Health Services, Express Scripts' Ascent Health Services, and OptumRx's Emisar Pharma Services. These subsidiaries allegedly negotiated and collected manufacturer payments that never made it back to plan sponsors and fell outside typical audit rights. For self-funded employers and public entities watching their pharmacy spend, that opacity is the heart of the matter.
The suit brings six causes of action, including claims under federal racketeering laws, the Illinois Antitrust Act, and common law fraud. The agency is seeking treble damages, disgorgement, and court orders to stop the alleged conduct.
No court has weighed in on the merits yet, and the defendants will have their chance to respond. But the case underscores growing scrutiny of PBM practices and the complicated money flows between drug makers, middlemen, and the insurers and employers who ultimately foot the bill.
For risk managers and benefits professionals, the litigation offers a window into how one self-insured pool is pushing back—and a reminder that the debate over drug pricing transparency is far from settled.
